Pearson 2021 Preliminary Results

Andy Bird, Pearson’s Chief Executive, said: “2021 has been a year of strong progress with the Group’s financial performance ahead of expectations. This reflects disciplined management of the business, operational execution, commitment of colleagues around the world and their ability to successfully navigate challenging market conditions.

Pearson has been reorganised and refocused with a new purpose to ‘add life to a lifetime of learning’ at the heart of everything we do. Our direct-to-consumer strategy is being driven by Pearson+, which had 2.75 million registered users at the end of 2021, with a strategy in place to engage more consumers and grow beyond Higher Education. Pearson is a digital first business, with consumer grade products, and the momentum across the company underpins our confidence for further growth in 2022 and beyond.”

Statutory results
• Sales increased 1% to £3,428m (2020: £3,397m), reflecting underlying performance, portfolio changes and currency movements.
• Statutory operating profit was £183m (2020: £411m). The decrease in 2021 is mainly due to the gain on sale of PRH recognised in 2020 and restructuring costs in 2021 partially offset by improved trading profits, reduced intangible charges and gains on the 2021 business disposals.
• Net cash generated from operations of £570m (2020: £450m).
• Statutory earnings per share of 21.1p (2020: 41.0p).
details at: https://plc.pearson.com/sites/pearson-corp/files/pearson/investors/results-presentations/pearson-2021-full-year-results–press-release.pdf

Related Posts

Aptar Pharma Acquires Device Technology Assets of SipNose

Aptar Pharma announces that it has acquired all device technology assets from the proprietary portfolio of SipNose Nasal Delivery Systems, a company focused on intranasal delivery platforms for local, systemic and central nervous system indications. SipNose offers a variety of devices that are designed and adapted to fit a wide range of therapies and offer the opportunity to precisely target areas of the nasal cavity to enable enhanced systemic, local or even direct-to-brain delivery. SipNose’s expanded innovative delivery systems, which include liquid and dry powder intranasal delivery, will further strengthen Aptar Pharma’s nose-to-brain pathway expertise and fuel additional development and new scientific research.

J.Crew Group, Inc. Announces Third Quarter Fiscal 2017 Results

•Total revenues decreased 5% to $566.7 million. Comparable company sales decreased 9% following a decrease of 8% in the third quarter last year. •J.Crew sales decreased 12% to $430.4 million. J.Crew comparable sales decreased 12% following a decrease of 9% in the third quarter last year. •Madewell sales increased 22% to $107.5 million. Madewell comparable sales increased 13% following an increase of 4% in the third quarter last year. •Gross margin increased to 40.1% from 38.1% in the third quarter last year. Click Read More below for additional information.

L&D Activities Led by AI? No Thanks, Say Workers in New Wiley Survey

Workers express little interest in seeing learning and development (L&D) activities taken over by artificial intelligence (AI), according to new survey data from Wiley. Nearly six in ten respondents (59%) in the latest Wiley Workplace Intelligence report, Artificial Intelligence in Learning and Development: Five Surprising Facts You Need to Know, say they prefer to see an instructor—in-person or virtual—direct their workforce development learning, while only 7% prefer AI-directed learning. In addition, the vast majority (87%) of respondents say they want the L&D content to be developed by a subject matter expert as opposed to AI technology (12%). “When it comes to learning and development, employees crave a human connection,” said Dr. Mark Scullard, senior director of product innovation at Wiley. “They want a person to create and lead their instruction, even if it’s in an online setting.”
Back To Top
×Close search
Search